Literature DB >> 12131678

Elimination of anti-Gal B cells by alpha-Gal ricin1.

Masahiro Tanemura1, Haruko Ogawa, Deng-Ping Yin, Zhao-Chun Chen, Verdi J DiSesa, Uri Galili.   

Abstract

BACKGROUND: A major barrier in pig to human organ transplantation is the binding of human anti-Gal to alpha-gal epitopes (Gal alpha 1-3Gal beta 1-4GlcNAc-R) on pig cells, resulting in hyperacute and acute vascular rejection of pig xenografts. Moreover, the immune system in xenograft recipients is activated by these epitopes to produce high affinity anti-Gal, which is also detrimental to xenografts. Production of anti-Gal can be prevented by specific elimination of anti-Gal B cells. This was achieved with the toxin ricin A, coupled to human alpha1-acid glycoprotein modified to carry alpha-gal epitopes. This complex, designated alpha-gal ricin, is targeted in vivo to anti-Gal B cells by interaction with the immunoglobulin molecules (i.e., B cell receptors) on these cells.
METHODS: Carbohydrate chains on alpha 1-acid glycoprotein were converted to carry alpha-gal epitopes by enzymatic treatment with recombinant alpha 1,3 galactosyltransferase (alpha 1,3GT). This molecule and ricin A were biotinylated and coupled by avidin to generate alpha-gal ricin. The efficacy of alpha-gal ricin in eliminating anti-Gal B cells was studied in the experimental model of alpha 1,3GT knockout (KO) mice. These mice produce large amounts of anti-Gal immunoglobulin G when immunized with pig kidney membranes, as measured by ELISA with alpha-gal epitopes linked to bovine serum albumin (BSA). In the absence of anti-Gal B cells, these mice lack the ability to produce anti-Gal.
RESULTS: Repeated administration of alpha-gal ricin into alpha1,3GT KO mice resulted in elimination of anti-Gal B cells, thereby preventing production of anti-Gal immunoglobulin G after immunization with pig kidney membranes. This prevention of anti-Gal production occurred with doses of alpha-gal ricin that were not toxic to the mice and did not affect production of antibodies with other specificities.
CONCLUSIONS: Administration of alpha-gal ricin results in specific elimination of anti-Gal B cells in alpha 1,3GT KO mice. The elimination of these B cells may prove to be helpful in attempts to achieve immune tolerance to alpha-gal epitopes in primates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12131678     DOI: 10.1097/00007890-200206270-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.

Authors:  Ussama Abdel-Motal; Shixia Wang; Shan Lu; Kim Wigglesworth; Uri Galili
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 2.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

3.  The anti-non-gal xenoantibody response to xenoantigens on gal knockout pig cells is encoded by a restricted number of germline progenitors.

Authors:  K Kiernan; I Harnden; M Gunthart; C Gregory; J Meisner; M Kearns-Jonker
Journal:  Am J Transplant       Date:  2008-07-28       Impact factor: 8.086

4.  Blockade of invariant TCR-CD1d interaction specifically inhibits antibody production against blood group A carbohydrates.

Authors:  Hirofumi Tazawa; Toshimitsu Irei; Yuka Tanaka; Yuka Igarashi; Hirotaka Tashiro; Hideki Ohdan
Journal:  Blood       Date:  2013-08-13       Impact factor: 22.113

5.  Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells.

Authors:  Ussama M Abdel-Motal; Heath M Guay; Kim Wigglesworth; Raymond M Welsh; Uri Galili
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

6.  Similarities in the immunoglobulin response and VH gene usage in rhesus monkeys and humans exposed to porcine hepatocytes.

Authors:  Joanne L Zahorsky-Reeves; Clare R Gregory; Donald V Cramer; Insiyyah Y Patanwala; Andrew E Kyles; Dominic C Borie; Mary K Kearns-Jonker
Journal:  BMC Immunol       Date:  2006-03-20       Impact factor: 3.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.